Ormaplatin | CAS#62816-98-2 | Platinum cancer drug | DNA-alkylating

MedKoo Cat#: 205984 | Name: Ormaplatin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ormaplatin is a platinum(IV) analogue with antineoplastic activity. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Chemical Structure

Ormaplatin

CAS#62816-98-2

Theoretical Analysis

MedKoo Cat#: 205984

Name: Ormaplatin

CAS#: 62816-98-2

Chemical Formula: C6H14Cl4N2Pt

Exact Mass:

Molecular Weight: 451.08

Elemental Analysis: C, 15.98; H, 3.13; Cl, 31.44; N, 6.21; Pt, 43.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Ormaplatin; tetraplatin.

IUPAC/Chemical Name

tetrachloro(1,2-cyclohexanediamine-N,N')-, (OC-6-22-(trans))platinum

InChi Key

KVFQUEDZECDHKS-UHFFFAOYSA-J

InChi Code

InChI=1S/C6H12N2.4ClH.Pt/c7-5-3-1-2-4-6(5)8;;;;;/h5-8H,1-4H2;4*1H;/q-2;;;;;+6/p-4

SMILES Code

[NH-]C1C([NH-])CCCC1.Cl[Pt+2](Cl)(Cl)Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 451.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Feierabend C, Robins HI, Spriggs DR, Wilding G. Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812). Invest New Drugs. 1999;17(1):63-72. PubMed PMID: 10555124. 2: Luo FR, Wyrick SD, Chaney SG. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Cancer Chemother Pharmacol. 1999;44(1):29-38. PubMed PMID: 10367746. 3: Luo FR, Wyrick SD, Chaney SG. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol. 1999;44(1):19-28. PubMed PMID: 10367745. 4: Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, Wyrick SD, Chaney SG. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci. 1998 Dec;46(2):342-51. PubMed PMID: 10048138. 5: Figg WD, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin. Biopharm Drug Dispos. 1997 May;18(4):347-59. PubMed PMID: 9158882. 6: Screnci D, Er HM, Hambley TW, Galettis P, Brouwer W, McKeage MJ. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer. 1997;76(4):502-10. PubMed PMID: 9275028; PubMed Central PMCID: PMC2227979. 7: Rischin D, Ling V. Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II). Br J Cancer. 1996 Aug;74(4):590-6. PubMed PMID: 8761375; PubMed Central PMCID: PMC2074663. 8: Thompson DC, Wyrick SD, Holbrook DJ, Chaney SG. Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma. Cancer Res. 1995 Jul 1;55(13):2837-46. PubMed PMID: 7796411. 9: Thompson DC, Vaisman A, Sakata MK, Wyrick SD, Holbrook DJ, Chaney SG. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat. Cancer Chemother Pharmacol. 1995;36(5):439-47. PubMed PMID: 7634386. 10: Sakata M, Chaney SG, Spriggs DR. Possible correlation between ormaplatin biotransformations and neurotoxicity. Oncol Res. 1995;7(2):67-71. PubMed PMID: 7579729.